Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells

Abstract

Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and / or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and / or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.

Description

[0001]This patent application is a continuation of U.S. Ser. No. 13 / 508,803 filed May 9, 2012, which is the National Stage of International Application No. PCT / US2010 / 055956, filed Nov. 9, 2010, which claims the benefit of priority from U.S. Provisional Application Ser. No. 61 / 326,799, filed Apr. 22, 2010 and U.S. Provisional Application Ser. No. 61 / 260,441, filed Nov. 12, 2009, teachings of each of which are herein incorporated by reference in their entireties.INTRODUCTIONField of the Invention[0002]The present invention provides manufacturing methods for a population of mammalian-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended cellular phenotypes and / or decreased standard deviation in the cells of the population as well as methods for use of these cells. Also provided in the present invention is an antibody panel to characterize GRPs and a method for its use in characterizing GRP cells.Background of the Invention[0003]Glial restricted progeni...

AI Technical Summary

Benefits of technology

The patent text describes methods for manufacturing specific types of brain cells, such as neurons, astrocytes, and oligodendrocytes. These methods can help generate more of these cells for research and potential treatment of neurological disorders. Additionally, the patent describes ways to decrease unwanted cell content and standard deviation in these brain cells. The patent also describes the use of antibodies to characterize these brain cells and gene expression profiles that can help identify them. Finally, the patent suggests that these manufactured brain cells can be used to remyelinate neurons and reduce glial scar formation. Overall, this patent provides technical means for studying and potentially treating brain disorders.

Problems solved by technology

Demyelinated neurons cannot properly conduct signals and eventually will die.

However, the majority of patients who experience demyelination due to various diseases or trauma do not experience sufficient endogenous remyelination (Prineas et al., Ann. Neurol. 1993 33:137-151), and despite much need and effort, little progress has been made in developing products that can help restore lost function.

Images